Company: LDDD
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001213900-25-042963
Chunk: 57

Company: Longduoduo Co Ltd
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 2
Chunk 57
---
  

    2025  
    2024  
    Change 

    (Unaudited)  
    (Unaudited)  
    $  
    % 
  
    Total revenue 
    $3,322,287  
    $5,718,060  
    $(2,395,773) 
     (42)%
  
    Cost of revenue 
     81,501  
     143,347  
     (61,846) 
     (43)%
  
    Gross Profit 
     3,240,786  
     5,574,713  
     (2,333,927) 
     (42)%
  
    Total operating expenses 
     2,819,107  
     4,026,082  
     (1,206,975) 
     (30)%
  
    Loss from operations 
     421,679  
     1,584,631  
     (1,126,952) 
     (73)%
  
    Other income (expense), net 
     10,756  
     (144,825) 
     155,581  
     (107)%
  
    Loss before income taxes 
     432,435  
     1,403,806  
     (971,371) 
     (69)%
  
    Income tax 
     106,660  
     408,265  
     (301,605) 
     (74)%
  
    Net income 
    $325,775  
    $995,541  
    $(669,766) 
     (67)%

During the nine months ended March 31, 2025, our
total revenue was $3,322,287, of which $117,640 was attributable to the sale of healthcare services, primarily derived from sales of “Immunological
Ozonated Autohemotherapy”, “Meridian-regulating and Consciousness-restoring Iatrotechnics”, “Assay”, “PRP”
and other healthcare services. The remaining $3,204,647 of revenue was attributable to commissions earned by the Company from its service
as sales agent for Honghai. In June of 2023, the Company began to engage in the sales agent business and focused on the sales of preventive
health